Upcoming Meetings: CLIA quality control meeting
This article was originally published in The Gray Sheet
Executive Summary
CLIA quality control meeting: Centers for Disease Control and Prevention schedules meeting for Sept. 25-26 to discuss "Quality Control Issues Relevant to Regulations Under the Clinical Laboratory Improvement Amendments" at CDC headquarters in Atlanta. Items on the agenda include: "the ability of current test systems to assess the potential for error in the total testing process"; "processes to monitor the quality of clinical laboratory results over time"; and "processes to assess appropriate operator performance." The committee will hear input from industry reps on the first day and other health professionals the second day; comments will be considered by CDC in the development of final CLIA regs for quality control. For further information, contact CDC's Julie Wasil at 770/488-4651...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.